Sebetralstat Patent Expiration
Sebetralstat was first introduced by Kalvista Pharmaceuticals Ltd
Sebetralstat Patents
Given below is the list of patents protecting Sebetralstat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ekterly | US11234939 | Dosage Forms Comprising A Plasma Kallikrein Inhibitor | Jan 26, 2039 | Kalvista |
| Ekterly | US11230537 | Polymorphs Of N-[(3-Fluoro-4-Methoxypyridin-2-Yl)Methyl]-3-(Methoxymethyl)-1-({4-[2-Oxopyridin-1-Yl)Methyl]Phenyl} Methyl)Pyrazole-4-Carboxamide As Iallikrein Inhibitors | Dec 25, 2037 | Kalvista |
| Ekterly | US11739068 | Polymorphs Of N-[(3-Fluoro-4-Methoxypyridin-2-Yl)Methyl]-3-(Methoxymethyl)-1-({4-[(2-Oxopyridin-1-Yl)Methyl]Phenyl}Methyl)Pyrazole-4-Carboxamide And Salts Thereof | Jun 23, 2037 | Kalvista |
| Ekterly | US10364238 | N-((Het) Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | Nov 26, 2035 | Kalvista |
| Ekterly | US10611758 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | Nov 26, 2035 | Kalvista |
| Ekterly | US11001578 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | Nov 26, 2035 | Kalvista |
| Ekterly | US11084809 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | Nov 26, 2035 | Kalvista |
| Ekterly | US11198691 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | Nov 26, 2035 | Kalvista |
Sebetralstat's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Sebetralstat:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial | KalVista Pharmaceuticals, Ltd. | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |